HomePSTV • NASDAQ
add
Plus Therapeutics Inc
Previous close
$0.26
Day range
$0.25 - $0.26
Year range
$0.16 - $2.08
Market cap
43.00M USD
Avg Volume
5.60M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | 1.37M | -3.19% |
Operating expense | 4.17M | 33.33% |
Net income | -5.71M | -46.37% |
Net profit margin | -417.92 | -51.19% |
Earnings per share | 0.00 | 100.00% |
EBITDA | -5.60M | -57.57% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 8.61M | 138.82% |
Total assets | 16.32M | 146.12% |
Total liabilities | 12.33M | -20.88% |
Total equity | 4.00M | — |
Shares outstanding | 171.55M | — |
Price to book | 8.69 | — |
Return on assets | -82.04% | — |
Return on capital | -176.22% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | -5.71M | -46.37% |
Cash from operations | -6.26M | -416.68% |
Cash from investing | -1.08M | -1,782.81% |
Cash from financing | 2.80M | — |
Net change in cash | -4.53M | -295.03% |
Free cash flow | -4.01M | -1,221.55% |
About
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecular diagnostic service, CNSide®. Wikipedia
Founded
1996
Headquarters
Website
Employees
21
